PDCD1 and cancer: Under the concurrent use of NAs, we observed an overall decrease in the levels of serum HBsAg in cancer patients receiving PD-1 inhibitor combinational therapy, with a small number of patients achieving HBsAg loss, and the viral replication of most patients can also be effectively inhibited.